Nurix insider plans sale of 16,589 common shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. (NRIX) reports that insider Christine Ring has filed to sell up to 16,589 shares of common stock, with an aggregate market value of $385,030.69, through Morgan Stanley Smith Barney LLC, with sales expected on or after August 3, 2026 on NASDAQ. The shares derive from an exercise of stock options for 5,787 shares on August 3, 2026 for cash and 10,802 restricted stock units vesting on July 30, 2025. The filing also lists prior Rule 10b5-1 sales over the past three months, including a sale of 28,935 shares for $580,506.12 on June 25, 2026, along with several smaller transactions.
Key Figures
Key Terms
Form 144 regulatory
10b5-1 Sales regulatory
Restricted Stock Units financial
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What recent NRIX stock sales under a Rule 10b5-1 plan are reported?
AI-generated analysis. How Rhea-AI works. Not financial advice.